

Remarks/Comments

This submission supplements the Response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which Response was filed by prior counsel on October 3, 2005. Submitted concurrently herewith is a Substitute Sequence Listing that is in compliance with the requirements set forth in 37 C.F.R. §§ 1.821-1.825. The Substitute Sequence Listing replaces in its entirety the Sequence Listing previously submitted on October 3, 2005. Support for the amendments presented herein may be found in the application as filed, and no new matter has been added.

The Substitute Sequence Listing corrects certain errors in the original Sequence Listing filed on October 3, 2005. For example, in the original Sequence Listing, certain sequences are identified as "Artificial" in field "<213>", but the source of the genetic material was not identified in field "<223>". The sources for all of the sequences in the Substitute Sequence Listing are properly identified.

The Substitute Sequence Listing is submitted as a paper copy (formatted as a PDF file in compliance with the USPTO's Electronic Filing System ("EFS-Web")), as well as a computer-readable file (formatted as an ASCII text file). The information recorded in the computer-readable form is identical to the written (paper) sequence listing.

Applicants hereby request any extension of time necessary for entry of this Amendment and Response. The commissioner is authorized to charge any required fees ("small entity" status) to Deposit Account No. 50-4364, from which the undersigned is authorized to draw.

Respectfully Submitted,
Saul Ewing LLP

Dated: December 14, 2007

Phone: (410) 332-8685
Fax: (410) 332-8085


Konstantine M. Katcheves
Attorney for Applicant
Reg. No. 54818
500 East Pratt Street
Baltimore, MD 21202